Boyuan Yao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Boyuan Yao has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Qilin Zhang
Department of Neurosurgery and National Center for Neurological Disorders Huashan Hospital, Shanghai Medical College, Fudan University Shanghai China
2 shared publications Yongfei Wang
2 shared publicationsZengyi Ma
2 shared publications- Chao Zhang
Department of Orthopedics and Precision Research Center for Refractory Diseases, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
1 shared publication - Fang Xie
Department of Nuclear Medicine & PET Center, Huashan Hospital, Fudan University, Shanghai, China
1 shared publication - Guoji Guo
Center for Stem Cell and Regenerative Medicine, Zhejiang University School of Medicine, Hangzhou, China
1 shared publication
Latest Publications
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (3) , e233469
Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using 68Ga-Pentixafor for Tumor Localization in Cushing Disease
In a prospective study involving 43 participants with Cushing disease, the incorporation of gallium 68 (68Ga) pentixafor PET/MRI demonstrated promising sensitivity, which was higher than contrast-enhanced MRI alone in localizing adrenocorticotropic hormone–secreting pituitary tumors.
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (3) , e233469
Diagnostic Accuracy and Value of CXCR4-targeted PET/MRI Using 68Ga-Pentixafor for Tumor Localization in Cushing Disease
In a prospective study involving 43 participants with Cushing disease, the incorporation of gallium 68 (68Ga) pentixafor PET/MRI demonstrated promising sensitivity, which was higher than contrast-enhanced MRI alone in localizing adrenocorticotropic hormone–secreting pituitary tumors.
- 24 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
Characterization of Somatotrope Cell Expansion in Response to GHRH in the Neonatal Mouse Pituitary
In humans and mice, loss-of-function mutations in growth hormone–releasing hormone receptor (GHRHR) cause isolated GH deficiency. The mutant GHRHR mouse model, GhrhrLit/Lit (LIT), exhibits loss of serum GH, but also fewer somatotropes. However, how loss of GHRH signaling affects expansion of stem and progenitor cells giving rise to GH-producing cells is unknown. LIT mice and wild-type littermates were examined for differences in proliferation and gene expression of pituitary lineage markers by quantitative reverse transcription polymerase chain reaction and immunohistochemistry at postnatal day 5 (p5) and 5 weeks. At p5, the LIT mouse shows a global decrease in pituitary proliferation measured by proliferation marker Ki67 and phospho-histone H3. This proliferative defect is seen in a pituitary cell expressing POU1F1 with or without GH. SOX9-positive progenitors show no changes in proliferation in p5 LIT mice. Additionally, the other POU1F1 lineage cells are not decreased in number; rather, we observe an increase in lactotrope cell population as well as messenger RNA for Tshb and Prl. In the 5-week LIT pituitary, the proliferative deficit in POU1F1-expressing cells observed neonatally persists, while the number and proliferative proportion of SOX9 cells do not appear changed. Treatment of cultured pituitary explants with GHRH promotes proliferation of POU1F1-expressing cells, but not GH-positive cells, in a mitogen-activated protein kinase–dependent manner. These findings indicate that hypothalamic GHRH targets proliferation of a POU1F1-positive cell, targeted to the somatotrope lineage, to fine tune their numbers.
- 24 August 2023
- Published by The Endocrine Society in Endocrinology
- Vol. 164 (10)
Characterization of Somatotrope Cell Expansion in Response to GHRH in the Neonatal Mouse Pituitary
In humans and mice, loss-of-function mutations in growth hormone–releasing hormone receptor (GHRHR) cause isolated GH deficiency. The mutant GHRHR mouse model, GhrhrLit/Lit (LIT), exhibits loss of serum GH, but also fewer somatotropes. However, how loss of GHRH signaling affects expansion of stem and progenitor cells giving rise to GH-producing cells is unknown. LIT mice and wild-type littermates were examined for differences in proliferation and gene expression of pituitary lineage markers by quantitative reverse transcription polymerase chain reaction and immunohistochemistry at postnatal day 5 (p5) and 5 weeks. At p5, the LIT mouse shows a global decrease in pituitary proliferation measured by proliferation marker Ki67 and phospho-histone H3. This proliferative defect is seen in a pituitary cell expressing POU1F1 with or without GH. SOX9-positive progenitors show no changes in proliferation in p5 LIT mice. Additionally, the other POU1F1 lineage cells are not decreased in number; rather, we observe an increase in lactotrope cell population as well as messenger RNA for Tshb and Prl. In the 5-week LIT pituitary, the proliferative deficit in POU1F1-expressing cells observed neonatally persists, while the number and proliferative proportion of SOX9 cells do not appear changed. Treatment of cultured pituitary explants with GHRH promotes proliferation of POU1F1-expressing cells, but not GH-positive cells, in a mitogen-activated protein kinase–dependent manner. These findings indicate that hypothalamic GHRH targets proliferation of a POU1F1-positive cell, targeted to the somatotrope lineage, to fine tune their numbers.
- Top Cited PapersOpen Access
- 20 September 2022
- Published by Springer Nature in Cell Discovery
- Vol. 8 (1) , 1-20
Single-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma
Skull base chordoma (SBC) is a bone cancer with a high recurrence rate, high radioresistance rate, and poorly understood mechanism. Here, we profiled the transcriptomes of 90,691 single cells, revealed the SBC cellular hierarchies, and explored novel treatment targets. We identified a cluster of stem-like SBC cells that tended to be distributed in the inferior part of the tumor. Combining radiated UM-Chor1 RNA-seq data and in vitro validation, we further found that this stem-like cell cluster is marked by cathepsin L (CTSL), a gene involved in the packaging of telomere ends, and may be responsible for radioresistance. Moreover, signatures related to partial epithelial–mesenchymal transition (p-EMT) were found to be significant in malignant cells and were related to the invasion and poor prognosis of SBC. Furthermore, YL-13027, a p-EMT inhibitor that acts through the TGF-β signaling pathway, demonstrated remarkable potency in inhibiting the invasiveness of SBC in preclinical models and was subsequently applied in a phase I clinical trial that enrolled three SBC patients. Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.
- 20 September 2022
- Published by Springer Nature in Cell Discovery
- Vol. 8 (1) , 1-20
Top Cited PapersOpen AccessSingle-cell transcriptome reveals cellular hierarchies and guides p-EMT-targeted trial in skull base chordoma
Skull base chordoma (SBC) is a bone cancer with a high recurrence rate, high radioresistance rate, and poorly understood mechanism. Here, we profiled the transcriptomes of 90,691 single cells, revealed the SBC cellular hierarchies, and explored novel treatment targets. We identified a cluster of stem-like SBC cells that tended to be distributed in the inferior part of the tumor. Combining radiated UM-Chor1 RNA-seq data and in vitro validation, we further found that this stem-like cell cluster is marked by cathepsin L (CTSL), a gene involved in the packaging of telomere ends, and may be responsible for radioresistance. Moreover, signatures related to partial epithelial–mesenchymal transition (p-EMT) were found to be significant in malignant cells and were related to the invasion and poor prognosis of SBC. Furthermore, YL-13027, a p-EMT inhibitor that acts through the TGF-β signaling pathway, demonstrated remarkable potency in inhibiting the invasiveness of SBC in preclinical models and was subsequently applied in a phase I clinical trial that enrolled three SBC patients. Encouragingly, YL-13027 attenuated the growth of SBC and achieved stable disease with no serious adverse events, underscoring the clinical potential for the precision treatment of SBC with this therapy. In summary, we conducted the first single-cell RNA sequencing of SBC and identified several targets that could be translated to the treatment of SBC.